van den Brink F S, Meijers T A, Hofma S H, van Boven A J, Nap A, Vonk A, Symersky P, Sjauw K D, Knaapen P
Department of Cardiology, Medisch Centrum Leeuwarden, Leeuwarden, The Netherlands.
Department of Cardiology, Location Vrije Universiteit Medisch Centrum, Amsterdam Universitair Medisch Centrum, Amsterdam, The Netherlands.
Neth Heart J. 2020 Mar;28(3):139-144. doi: 10.1007/s12471-019-01350-8.
Complex high-risk percutaneous coronary intervention (PCI) is challenging and frequently accompanied by haemodynamic instability. Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) can provide cardiopulmonary support in high-risk PCI. However, the outcome is unclear.
A two-centre, retrospective study was performed of all patients undergoing high-risk PCI and receiving VA-ECMO for cardiopulmonary support.
A total of 14 patients (92% male, median age 69 (53-83) years), of whom 50% had previous coronary artery disease in the form of a coronary artery bypass graft (36%) and a PCI (14%) underwent high-risk PCI and received VA-ECMO support. The main target lesion was a left main coronary artery in 78%, a left anterior descending artery in 14%, a right coronary artery in 7%, and 71% underwent multi-vessel PCI in addition to main target vessel PCI. The median SYNTAX score was 27.2 (8-42.5) and in 64% (9/14) there was a chronic total occlusion. Left ventricular function was mildly impaired in 7% (1/14), moderately impaired in 14% (2/14) and severely impaired in 64% (9/14). Cannulation was femoral-femoral in all patients. Median ECMO run was 2.57 h (1-4). Survival was 93% (13/14). One patient died during hospitalisation due to refractory cardiac failure. All other patients survived to discharge. Complications occurred in 14% (2/14), with one patient developing a transient ischaemic attack post-ECMO and one patient developing a thrombus in the femoral vein used for ECMO cannulation.
VA-ECMO in high-risk PCI is feasible with a good outcome. It can be successfully used for cardiopulmonary support in selected patients.
复杂的高风险经皮冠状动脉介入治疗(PCI)具有挑战性,且常伴有血流动力学不稳定。静脉-动脉体外膜肺氧合(VA-ECMO)可为高风险PCI提供心肺支持。然而,其结果尚不清楚。
对所有接受高风险PCI并接受VA-ECMO心肺支持的患者进行了一项双中心回顾性研究。
共有14例患者(92%为男性,中位年龄69(53 - 83)岁)接受了高风险PCI并接受VA-ECMO支持,其中50%既往有冠状动脉疾病,形式为冠状动脉旁路移植术(36%)和PCI(14%)。主要靶病变为左主干冠状动脉的占78%,左前降支动脉的占14%,右冠状动脉的占7%,71%除主要靶血管PCI外还接受了多支血管PCI。中位SYNTAX评分为27.2(8 - 42.5),64%(9/14)存在慢性完全闭塞。7%(1/14)的患者左心室功能轻度受损,14%(2/14)的患者中度受损,64%(9/14)的患者重度受损。所有患者均采用股-股插管。ECMO中位运行时间为2.57小时(1 - 4小时)。生存率为93%(13/14)。1例患者因难治性心力衰竭在住院期间死亡。所有其他患者均存活至出院。并发症发生率为14%(2/14),1例患者在ECMO后发生短暂性脑缺血发作,1例患者在用于ECMO插管的股静脉形成血栓。
高风险PCI中使用VA-ECMO是可行的,且预后良好。它可成功用于选定患者的心肺支持。